Clinical outcomes in sarcoidosis after cessation of infliximab treatment

Respirology

Volumn 14, Issue 4, 2009, Pages 522-528

  Panselinas, Efstratios ^a,b   Rodgers, J Keith ^c   Judson, Marc A ^a  

^a Division of Pulmonary and Critical Care Medicine   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Clinical outcome; Infliximab; Sarcoidosis; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HUMAN; KAPLAN MEIER METHOD; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SARCOIDOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 65649120705     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01518.x     Document Type: Article

References (34)

1. Bradley D, Baughman RP, Raymond L, Kaufman AH. Ocular manifestations of sarcoidosis. Semin. Respir. Crit. Care Med. 2002 23 : 543 8.
2. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am. J. Cardiol. 2001 88 : 1006 10. (Pubitemid 33042612)
3. Vinas FC, Rengachary S. Diagnosis and management of neurosarcoidosis. J. Clin. Neurosci. 2001 8 : 505 13. (Pubitemid 33089498)
4. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999 115 : 1158 65. (Pubitemid 29193691)
5. Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin. Chest Med. 1997 18 : 843 51. (Pubitemid 27525445)
6. Mana J, Marcoval J, Graells J, Salazar A, Peyri J et al. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch. Dermatol. 1997 133 : 882 8. (Pubitemid 27337549)
7. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005 127 : 1064 71. (Pubitemid 40775543)
8. Sharma OP, Vucinic V. Sarcoidosis of the thyroid and kidneys and calcium metabolism. Semin. Respir. Crit. Care Med. 2002 23 : 579 88. (Pubitemid 36026371)
9. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin. Chest Med. 1997 : 18 : 853 64. (Pubitemid 27525446)
10. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am. J. Med. Sci. 1990 299 : 153 7. (Pubitemid 20085232)
11. Zheng L, Teschler H, Guzman J, Hubner K, Striz I et al. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am. J. Respir. Crit. Care Med. 1995 152 : 1061 6.
12. Steffen M, Petersen J, Oldigs M, Karmeier A, Magnussen H et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J. Allergy Clin. Immunol. 1993 91 : 939 49. (Pubitemid 23118511)
13. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin. Rheumatol. 2007 26 : 2001 3. (Pubitemid 47516998)
14. Ahmed MM, Mubashir E, Dossabhoy NR. Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin. Rheumatol. 2007 26 : 1346 9. (Pubitemid 47034195)
15. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can. J. Ophthalmol. 2006 41 : 766 8. (Pubitemid 46113034)
16. Mandel L, Wolinsky B, Chalom EC. Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case. J. Am. Dent. Assoc. 2005 136 : 1282 5. (Pubitemid 41366288)
17. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003 48 : 3542 3. (Pubitemid 37531922)
18. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003 124 : 2028 31. (Pubitemid 37433610)
19. Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J. Am. Acad. Dermatol. 2003 48 : 290 3. (Pubitemid 36232335)
20. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch. Neurol. 2003 60 : 426 30. (Pubitemid 36314369)
21. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann. Intern. Med. 2001 135 : 27 31. (Pubitemid 32619280)
22. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir. Med. 2006 100 : 2053 9. (Pubitemid 44514944)
23. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005 53 : 788 91. (Pubitemid 41463847)
24. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann. Rheum. Dis. 2004 63 : 318 20. (Pubitemid 38250677)
25. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 2006 174 : 795 802. (Pubitemid 44511661)
26. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur. Respir. J. 2008 31 : 1189 96.
27. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 1999 16 : 75 86.
28. Pagano M, Gauvreau K. Principles of Biostatistics. Duxbury Press, Belmont CA, 1993.
29. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin. Gastroenterol. Hepatol. 2007 5 : 729 35, e721. (Pubitemid 46830051)
30. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 295 : 2275 85. (Pubitemid 43736578)
31. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001 345 : 1098 104.
32. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev. 2005 2 : CD001114, 1 32.
33. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006 61 : 68 74. (Pubitemid 43106981)
34. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 2007 66 : 1252 4. (Pubitemid 47309746)